CalciMedica (CALC)
NASDAQ:CALC
Want to see CALC full AI Analyst Report?
CALC Stock Chart & Stats
$0.60
<$0.01(0.05%)
At close: 4:00 PM EST
$0.60
<$0.01(0.05%)
Day’s Range― - ―
52-Week Range$0.46 - $7.20
Previous CloseN/A
Volume2.29K
Average Volume (3M)71.94K
Market Cap
$12.65M
Enterprise Value$4.74M
Total Cash (Recent Filing)$8.16M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Aug 18, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding15,798,031
10 Day Avg. Volume167,963
30 Day Avg. Volume71,939
Financial Highlights & Ratios
PEG Ratio-54.43
Price to Book (P/B)-14.90K
Price to Sales (P/S)0.00
P/FCF Ratio-4.66K
Enterprise Value/Market Cap0.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-677.57
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$10.00Price Target Upside1566.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.62
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused CRAC Inhibitor Platform (Auxora)A clear, platform-focused R&D strategy centered on CRAC channel inhibition and Auxora provides durable scientific differentiation. A mechanism‑driven pipeline targeting inflammatory and immunologic indications supports potential multi-indication development and long-term value if clinical progress continues.
Zero Reported Debt (TTM)No reported debt in the trailing twelve months reduces interest and refinancing pressure, improving financial flexibility. For a pre-revenue biotech, low leverage lowers insolvency risk and gives management more options to time equity raises, partnerships, or milestone-based financing.
Narrowing Losses And Improved Cash Flow TrendA multi-year improvement in net losses and a reduction in free cash flow burn suggests better cost control or program prioritization. Sustained improvement makes runway more predictable, lowers immediate financing pressure, and enhances the company's ability to execute clinical programs over the medium term.
Bears Say
Pre-revenue With $0 Historical RevenueHaving no product revenue means the company cannot self-fund development and must rely on external capital, partnerships, or milestone payments. This structural dependence increases dilution risk, constrains strategic autonomy, and persists until regulatory or commercial milestones are achieved.
Sustained Heavy Cash Burn And Negative FCFOngoing negative operating and free cash flow at material levels necessitates frequent capital raises. That continual funding requirement increases dilution risk, can force strategic trade-offs, and may delay development timelines if financing conditions deteriorate, affecting long-term program execution.
Nasdaq Deficiency Notices Risking DelistingNon-compliance with Nasdaq listing standards creates structural risk to liquidity and investor access. Potential delisting or forced corporate actions (reverse splits) can reduce institutional interest, complicate future financings, and materially hinder long-term capital raising and strategic partnerships.
CalciMedica News
CALC FAQ
What was CalciMedica’s price range in the past 12 months?
CalciMedica lowest stock price was $0.46 and its highest was $7.20 in the past 12 months.
What is CalciMedica’s market cap?
CalciMedica’s market cap is $12.65M.
When is CalciMedica’s upcoming earnings report date?
CalciMedica’s upcoming earnings report date is Aug 18, 2026 which is in 75 days.
How were CalciMedica’s earnings last quarter?
CalciMedica released its earnings results on May 12, 2026. The company reported $0.3 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.58.
Is CalciMedica overvalued?
According to Wall Street analysts CalciMedica’s price is currently Undervalued.
Does CalciMedica pay dividends?
CalciMedica does not currently pay dividends.
What is CalciMedica’s EPS estimate?
CalciMedica’s EPS estimate is -0.27.
How many shares outstanding does CalciMedica have?
CalciMedica has 15,798,031 shares outstanding.
What happened to CalciMedica’s price movement after its last earnings report?
CalciMedica reported an EPS of $0.3 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went up 6.599%.
Which hedge fund is a major shareholder of CalciMedica?
Currently, no hedge funds are holding shares in CALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CalciMedica
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
CALC Stock 12 Month Forecast
Average Price Target
$10.00
▲(1566.67% Upside)
Technical Analysis
Ownership Overview
31.85% Insiders
1.58% Mutual Funds
1.46% Other Institutional Investors
64.54% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---